Intervention not reported
Shoulder range of motion for forward flexion ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Lymphoedema ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
It is very uncertain whether early shoulder mobilising exercises changes lymphoedema ‐ medium term compared with delayed shoulder mobilising exercises (very low certainty).
1 finding from 1 review
Shoulder range of motion for abduction ‐ short term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Survival ‐ overall · Women (70 years plus) with operable primary breast cancer
Surgery showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
1 finding from 1 review
Survival ‐ overall · Women (70 years plus) with operable primary breast cancer
Surgery plus endocrine therapy showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
1 finding from 1 review
Local tumor control · Women (70 years plus) with operable primary breast cancer
Surgery plus endocrine therapy leads to lower local disease control compared with primary endocrine therapy (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · patients with HER2‐positive metastatic breast cancer
The intervention probably leads to lower overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · patients with HER2‐positive metastatic breast cancer
The intervention probably leads to lower progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Congestive heart failure · patients with HER2‐positive metastatic breast cancer
The intervention probably leads to higher congestive heart failure (moderate certainty).
1 finding from 1 review
Incidence of postoperativeseromaRR · people with breast and axillary surgery
Fibrin glue instillation under skin flaps showed no clear difference in incidence of postoperativeseromaRR compared with no‐fibrin (low certainty).
1 finding from 1 review
Mean volume of seromaSMD · people with breast and axillary surgery
1 finding from 1 review
Total volume of drained seromaSMD · people with breast and axillary surgery
1 finding from 1 review
Number of days for persistent drainageSMD · people with breast and axillary surgery
1 finding from 1 review
Surgical site infection · people with breast and axillary surgery
Fibrin glue instillation under skin flaps showed no clear difference in surgical site infectionRR compared with no‐fibrin (low certainty).
1 finding from 1 review
PostoperativecomplicationsRR · people with breast and axillary surgery
Fibrin glue instillation under skin flaps showed no clear difference in postoperativecomplicationsRR compared with no‐fibrin (low certainty).
1 finding from 1 review
Length of hospital stay (theoretical) · people with breast and axillary surgery
1 finding from 1 review
Intervention not reported
Overall survival (OS) · HER2‐positive early breast cancer patients
The intervention leads to lower overall survival (OS) (high certainty).
1 finding from 1 review
Intervention not reported
Disease free survival (DFS) · HER2‐positive early breast cancer patients
The intervention leads to lower disease free survival (DFS) (high certainty).
1 finding from 1 review
Intervention not reported
Congestive heart failure (CHF) · HER2‐positive early breast cancer patients
The intervention leads to higher congestive heart failure (CHF) (high certainty).
1 finding from 1 review
Intervention not reported
Left ventricular ejection fraction decline (LVEF) · HER2‐positive early breast cancer patients
The intervention probably leads to higher left ventricular ejection fraction decline (LVEF) (moderate certainty).
1 finding from 1 review